Lipoprotein-Like Nanoparticle Carrying Small Interfering RNA Against Spalt-Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
16
10
2019
accepted:
29
01
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Patients with advanced hepatocellular carcinoma (HCC) are often unable to tolerate chemotherapy due to liver dysfunction in the setting of cirrhosis. We investigate high-density lipoprotein (HDL)-mimicking peptide phospholipid scaffold (HPPS), which are nanoparticles that capitalize on normal lipoprotein metabolism and transport, as a solution for directed delivery of small interfering RNA (siRNA) cargo into HCC cells. Spalt-like transcription factor 4 (SALL4), a fetal oncoprotein expressed in aggressive HCCs, is specifically targeted as a case study to evaluate the efficacy of HPPS carrying siRNA cargo. HPPS containing different formulations of siRNA therapy against SALL4 were generated specifically for HCC cells. These were investigated both
Identifiants
pubmed: 32363325
doi: 10.1002/hep4.1493
pii: HEP41493
pmc: PMC7193129
doi:
Types de publication
Journal Article
Langues
eng
Pagination
769-782Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Int J Mol Med. 2016 Nov;38(5):1587-1595
pubmed: 28026002
Br J Surg. 2011 Sep;98(9):1292-300
pubmed: 21656513
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4628-33
pubmed: 11274375
Gastroenterology. 2009 Mar;136(3):1000-11
pubmed: 19185577
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Jan-Feb;6(1):1-14
pubmed: 24339356
J Pathol Transl Med. 2015 Sep;49(5):373-81
pubmed: 26265684
Oncogene. 2017 Apr 27;36(17):2435-2445
pubmed: 27797380
Aliment Pharmacol Ther. 2013 Oct;38(7):703-12
pubmed: 23957569
Angew Chem Int Ed Engl. 2012 Mar 5;51(10):2429-33
pubmed: 22267090
World J Gastroenterol. 2016 Jan 21;22(3):1260-78
pubmed: 26811663
AACN Adv Crit Care. 2017 Summer;28(2):93-101
pubmed: 28592464
Pharm Res. 2014 Jun;31(6):1438-49
pubmed: 23625096
Hepatology. 2013 Apr;57(4):1469-83
pubmed: 23175232
Small. 2014 Aug 13;10(15):3072-82
pubmed: 24706435
Nanomedicine (Lond). 2012 Dec;7(12):1813-25
pubmed: 22830501
Blood. 2008 Aug 1;112(3):805-13
pubmed: 18487508
Eur J Cancer. 2018 Dec;105:1-9
pubmed: 30384012
Oncotarget. 2016 Nov 8;7(45):74059-74073
pubmed: 27677076
Am J Surg Pathol. 2014 Jul;38(7):966-72
pubmed: 24805857
Genes Dis. 2017 Jun;4(2):43-63
pubmed: 28944281
Mol Biol Cell. 2002 Jun;13(6):1929-39
pubmed: 12058060
J Immunol Res. 2014;2014:262385
pubmed: 24860834
Angew Chem Int Ed Engl. 2009;48(48):9171-5
pubmed: 19876988
J Hepatol. 2014 Jan;60(1):127-34
pubmed: 24012616
Eur J Clin Invest. 2011 Feb;41(2):221-32
pubmed: 20964680
Science. 1996 Jan 26;271(5248):518-20
pubmed: 8560269
N Engl J Med. 2013 Jun 13;368(24):2266-76
pubmed: 23758232
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17757-62
pubmed: 16306263
World J Gastroenterol. 2016 Mar 7;22(9):2837-43
pubmed: 26973422
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Methods Mol Biol. 2016;1444:153-66
pubmed: 27283425
Nat Mater. 2011 Apr;10(4):324-32
pubmed: 21423187
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Nanomedicine (Lond). 2014 Jan;9(1):105-20
pubmed: 24354813
Nanomedicine (Lond). 2011 Jun;6(4):631-41
pubmed: 21718175
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7119-E7128
pubmed: 29976840
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345